KaloBios (KBIO) is now in Oversold Territory - Tale of the Tape

By Zacks Equity Research,

Shutterstock photo

KaloBios Pharmaceuticals Inc's ( KBIO ) share price has entered into oversold territory with an RSI value of 29.9. The Zacks Consensus Estimate for KaloBios for the full year period has improved 8 cents over the past two months to -$1.40 per share. Currently, KaloBios has a Zacks Rank #2 (Buy), suggesting that now might be a good time to get in on ( KBIO ) after its recent drop.

KALOBIOS PHARMA (KBIO): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing , Investing Ideas , Stocks
Referenced Stocks: KBIO

More from Zacks.com




Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com